- 2024/08/07Press Release
- The results of a study on the usefulness of sublingual vaccines in influenza made the cover of the scientific journal Vaccines.
- 2024/03/04Press Release
- Biotube Co., Ltd. became the subsidiary of EPS Innovative Medicine (Japan) Co., Ltd.
- 2023/12/22Press Release
- The enrolment of patients has been initiated in the investigator-initiated clinical trials to which FEF Pharmaceutical Co., Ltd. provides investigational drugs
- 2023/12/21Press Release
- Be selected as a FINALIST at 2023 JINJI LAKE Innovation & Entrepreneurship Competition
- 2023/11/15Press Release
- Patients with allergic rhinitis and allergic to cedar pollinosis have lower saliva-secretory IgA than healthy subjects
- 2023/09/29Press Release
- Concluded a jointresearch agreementwith C-HAS+ Co., Ltd. for xploring useful substances for anti-obesity contained in natural products
- 2023/09/25Press Release
- Having prospect for the development of simple, highly effective and safe sublingual vaccines
- 2023/06/16Press Release
- Joint R&D Agreement for Regenerative Medicine Using Brown Adipocytes (for Slimming/weight loss)Concluded with Medical Corporation Tomoshibikai FIRE CLINIC
- 2023/04/01News
- Notice of Change of Representative Director
- 2023/02/21News
- FEF Pharmaceutical Co., Ltd. and Kyoto University have initiated a collaborative research project aimed at developing a novel treatment for lower extremity artery disease (LEAD).
-
EPS Innovative Medicine
(Japan) Co., Ltd. isA drug discovery company newly launched by the EPS Group on its 30th anniversary,
which aims to be a solution provider for the health industry.
SWIPESCROLL